Abstract
BackgroundImmunotherapy has made a significant impact in treating cancer, yet more than 40% of the patients remain unresponsive or have a short-lived response to therapy. Rationally designed combinations of targeted...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
